Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleOncology Drug Reference Sheet: Cabozantinib (Cabometyx®).AuthorsWiley, KathleenAbstractThe article reports that Cabozantinib received an additional U.S. Food and Drug Administration (FDA)-approved indication in January 2019for use in patients with hepatocellular carcinoma (HCC) who have already been treated with sorafenib.SubjectsANTINEOPLASTIC agents; ONCOLOGY nursing; DRUG interactions; HEPATOCELLULAR carcinoma; RENAL cell carcinoma; SAFETY; UNITED States. Food &; Drug Administration; DRUG approval; PROTEIN-tyrosine kinase inhibitors; SORAFENIB; THERAPEUTICSPublicationONS Voice, 2019, Vol 34, Issue 4, p36ISSN2475-6938Publication typeArticle